ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Dysstasia,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
1,2,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
1,3,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
1,4,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
1,5,Injection site warmth,Injection site reactions,Administration site reactions,Genrl,N
1,6,Tenderness,Pain and discomfort NEC,General system disorders NEC,Genrl,N
2,1,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
3,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
4,1,Injection site vesicles,Injection site reactions,Administration site reactions,Genrl,N
5,1,Dermatitis exfoliative generalised,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
5,2,Eye disorder,Ocular disorders NEC,Eye disorders NEC,Eye,N
5,3,Nail disorder,Nail and nail bed conditions (excl infections and infestations),Skin appendage conditions,Skin,N
6,1,Transaminases increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
7,1,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
8,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
9,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
9,2,Injection site haematoma,Injection site reactions,Administration site reactions,Genrl,N
9,3,Injection site injury,Injection site reactions,Administration site reactions,Genrl,N
9,4,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
9,5,Injection site warmth,Injection site reactions,Administration site reactions,Genrl,N
10,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
10,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
11,1,Penile size reduced,Penile disorders NEC (excl erection and ejaculation),Penile and scrotal disorders (excl infections and inflammations),Repro,N
11,2,Rhinorrhoea,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
12,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
13,1,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
13,2,Blood urea increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
13,3,Glomerular filtration rate decreased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
14,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
15,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
15,2,Injection site fibrosis,Injection site reactions,Administration site reactions,Genrl,N
15,3,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
15,4,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
16,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
16,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
16,3,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
17,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
17,2,Injection site induration,Injection site reactions,Administration site reactions,Genrl,N
17,3,Injection site inflammation,Injection site reactions,Administration site reactions,Genrl,N
17,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
17,5,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
17,6,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
18,1,Influenza,Influenza viral infections,Viral infectious disorders,Infec,N
18,2,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
19,1,Abdominal pain lower,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
19,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
19,3,Inflammation,Inflammations,General system disorders NEC,Genrl,N
19,4,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
20,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
20,2,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
20,3,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
20,4,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
21,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
21,2,Injection site induration,Injection site reactions,Administration site reactions,Genrl,N
21,3,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
21,4,Injection site warmth,Injection site reactions,Administration site reactions,Genrl,N
21,5,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
22,1,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
23,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
24,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
25,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
25,2,Agitation,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
25,3,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
25,4,Delusion,Delusional symptoms,Disturbances in thinking and perception,Psych,N
25,5,"Hallucination, visual",Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
25,6,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
25,7,Intentional self-injury,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
25,8,Panic attack,Panic attacks and disorders,Anxiety disorders and symptoms,Psych,N
25,9,Psychotic disorder,Psychotic disorder NEC,Schizophrenia and other psychotic disorders,Psych,N
25,10,Suicidal ideation,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
26,1,Spinal cord compression,Spinal cord and nerve root disorders NEC,Spinal cord and nerve root disorders,Nerv,N
27,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
27,2,Injection site induration,Injection site reactions,Administration site reactions,Genrl,N
27,3,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
27,4,Injection site warmth,Injection site reactions,Administration site reactions,Genrl,N
28,1,Blood testosterone increased,Reproductive hormone analyses,Endocrine investigations (incl sex hormones),Inv,N
28,2,Metastasis,Metastases to unknown and unspecified sites,Metastases,Neopl,N
28,3,Product administration error,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
28,4,Prostatic specific antigen decreased,Cell marker analyses,Cytogenetic investigations and genetic analyses,Inv,N
29,1,Affect lability,Affect alterations NEC,Mood disorders and disturbances NEC,Psych,N
29,2,Aggression,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
29,3,Anger,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
29,4,Crying,General signs and symptoms NEC,General system disorders NEC,Genrl,N
29,5,Psychotic disorder,Psychotic disorder NEC,Schizophrenia and other psychotic disorders,Psych,N
30,1,Inflammation,Inflammations,General system disorders NEC,Genrl,N
30,2,Purpura,Purpura and related conditions,Skin vascular abnormalities,Skin,N
30,3,Skin warm,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
31,1,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
32,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
32,2,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
32,3,Injection site induration,Injection site reactions,Administration site reactions,Genrl,N
32,4,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
32,5,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
32,6,Skin swelling,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
32,7,Skin warm,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
33,1,Influenza like illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
33,2,Irritability,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
33,3,Paranoia,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
33,4,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
34,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
34,2,Injection site induration,Injection site reactions,Administration site reactions,Genrl,N
34,3,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
34,4,Injection site warmth,Injection site reactions,Administration site reactions,Genrl,N
35,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
35,2,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
35,3,Injection site urticaria,Injection site reactions,Administration site reactions,Genrl,N
35,4,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
36,1,Erythema multiforme,Bullous conditions,Epidermal and dermal conditions,Skin,N
36,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
36,3,Product administration error,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
36,4,Product preparation error,Product preparation errors and issues,Medication errors and other product use errors and issues,Inj&P,N
37,1,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
37,2,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
38,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
39,1,Bladder cancer,Bladder neoplasms malignant,Renal and urinary tract neoplasms malignant and unspecified,Neopl,N
39,2,Cholelithiasis,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
39,3,Hepatic function abnormal,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
39,4,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
39,5,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
39,6,Pancreatic carcinoma metastatic,Pancreatic neoplasms malignant (excl islet cell and carcinoid),Gastrointestinal neoplasms malignant and unspecified,Neopl,N
39,7,Prostate cancer,Prostatic neoplasms malignant,Reproductive neoplasms male malignant and unspecified,Neopl,N
39,8,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
40,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
40,2,Wrong patient received product,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
41,1,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
42,1,Injection site cellulitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
42,2,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
42,3,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
43,1,Injection site bruising,Injection site reactions,Administration site reactions,Genrl,N
43,2,Injection site inflammation,Injection site reactions,Administration site reactions,Genrl,N
43,3,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
44,1,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
44,2,Injection site warmth,Injection site reactions,Administration site reactions,Genrl,N
44,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
44,4,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
45,1,Application site pain,Application site reactions,Administration site reactions,Genrl,N
45,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
45,3,Pustule,Skin structures and soft tissue infections,Infections - pathogen unspecified,Infec,N
45,4,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
46,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
46,2,Injection site inflammation,Injection site reactions,Administration site reactions,Genrl,N
46,3,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
47,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
47,2,Feeling hot,Feelings and sensations NEC,General system disorders NEC,Genrl,N
47,3,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
48,1,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
48,2,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
48,3,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
48,4,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
48,5,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
48,6,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
48,7,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
48,8,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
48,9,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
49,1,Cardiac arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
49,2,Cardiovascular disorder,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
49,3,Death,Death and sudden death,Fatal outcomes,Genrl,Y
50,1,Abdominal wall abscess,Abdominal and gastrointestinal infections,Infections - pathogen unspecified,Infec,N
50,2,Abscess,Infections NEC,Infections - pathogen unspecified,Infec,N
50,3,Injection site haematoma,Injection site reactions,Administration site reactions,Genrl,N
51,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
51,2,Injection site inflammation,Injection site reactions,Administration site reactions,Genrl,N
51,3,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
52,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
52,2,Feeling cold,Feelings and sensations NEC,General system disorders NEC,Genrl,N
52,3,Influenza like illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
52,4,Influenza like illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
52,5,Injection site infection,Infections NEC,Infections - pathogen unspecified,Infec,N
53,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
54,1,Anaphylactic shock,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
54,2,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
54,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
55,1,Abdominal abscess,Abdominal and gastrointestinal infections,Infections - pathogen unspecified,Infec,N
55,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
55,3,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
56,1,Balance disorder,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
56,2,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
56,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
56,4,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
57,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
57,2,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
57,3,Injection site warmth,Injection site reactions,Administration site reactions,Genrl,N
57,4,Skin hypertrophy,Skin hyperplasias and hypertrophies,Cornification and dystrophic skin disorders,Skin,N
58,1,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
58,2,Rectal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
59,1,Cellulitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
60,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
61,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
61,2,Unresponsive to stimuli,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
62,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
62,2,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
62,3,Inflammation,Inflammations,General system disorders NEC,Genrl,N
62,4,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
62,5,Skin induration,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
62,6,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
63,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
63,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
63,3,Injection site warmth,Injection site reactions,Administration site reactions,Genrl,N
64,1,Influenza like illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
64,2,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
65,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
65,2,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
65,3,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
66,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
66,2,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
66,3,Rash macular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
67,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
68,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
68,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
68,3,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
69,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
69,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
69,3,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
70,1,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
70,2,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
70,3,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
70,4,Injection site warmth,Injection site reactions,Administration site reactions,Genrl,N
70,5,Peripheral coldness,"Peripheral vasoconstriction, necrosis and vascular insufficiency","Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
70,6,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
71,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
72,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
72,2,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
72,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
72,4,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
72,5,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
73,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
73,2,Injection site inflammation,Injection site reactions,Administration site reactions,Genrl,N
74,1,Abnormal weight gain,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
74,2,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
74,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
74,4,Gastrointestinal disorder,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
74,5,Hypotonia,Muscle tone abnormal,Neuromuscular disorders,Nerv,N
74,6,Muscular weakness,Muscle weakness conditions,Muscle disorders,Musc,N
75,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
76,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
77,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
77,2,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
77,3,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
78,1,Injection site induration,Injection site reactions,Administration site reactions,Genrl,N
79,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
80,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
80,2,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
81,1,Adverse drug reaction,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
81,2,Blood testosterone decreased,Reproductive hormone analyses,Endocrine investigations (incl sex hormones),Inv,N
81,3,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
82,1,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
82,2,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
82,3,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
83,1,Injection site induration,Injection site reactions,Administration site reactions,Genrl,N
83,2,Injection site inflammation,Injection site reactions,Administration site reactions,Genrl,N
83,3,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
84,1,Hypersomnia,Narcolepsy and hypersomnia,Sleep disturbances (incl subtypes),Nerv,N
85,1,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
85,2,Feeling cold,Feelings and sensations NEC,General system disorders NEC,Genrl,N
85,3,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
86,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
86,2,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
86,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
87,1,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
87,2,Prostatic specific antigen increased,Cell marker analyses,Cytogenetic investigations and genetic analyses,Inv,N
88,1,Injection site haemorrhage,Injection site reactions,Administration site reactions,Genrl,N
88,2,Injection site vesicles,Injection site reactions,Administration site reactions,Genrl,N
88,3,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
89,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
89,2,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
90,1,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
90,2,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
90,3,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
91,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
92,1,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
93,1,Adverse event,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
93,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
94,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
94,2,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
94,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
95,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
95,2,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
96,1,Administration site erythema,Administration site reactions NEC,Administration site reactions,Genrl,N
96,2,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
97,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
97,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
98,1,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
99,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
99,2,Product use complaint,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
100,1,Injury associated with device,Complications associated with device NEC,Complications associated with device,Genrl,N
100,2,Needle issue,Device physical property and chemical issues,Device issues,Prod,N
101,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
101,2,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
102,1,Injection site discomfort,Injection site reactions,Administration site reactions,Genrl,N
103,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
104,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
105,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
106,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
107,1,Influenza like illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
107,2,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
107,3,Nodule,Mass conditions NEC,Tissue disorders NEC,Genrl,N
108,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
109,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
109,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
110,1,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
111,1,Hot flush,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
112,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
112,2,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
112,3,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
112,4,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
113,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
114,1,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
115,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
115,2,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
115,3,Product administered at inappropriate site,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
116,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
116,2,Injection site induration,Injection site reactions,Administration site reactions,Genrl,N
116,3,Product administered at inappropriate site,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
117,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
118,1,Discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
118,2,Skin disorder,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
119,1,Discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
119,2,Injection site irritation,Injection site reactions,Administration site reactions,Genrl,N
119,3,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
120,1,Inflammation,Inflammations,General system disorders NEC,Genrl,N
120,2,Influenza like illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
121,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
121,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
122,1,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
123,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
123,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
124,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
124,2,Injection site exfoliation,Injection site reactions,Administration site reactions,Genrl,N
124,3,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
124,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
124,5,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
125,1,Abdominal abscess,Abdominal and gastrointestinal infections,Infections - pathogen unspecified,Infec,N
125,2,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
126,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
127,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
128,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
129,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
130,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
131,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
131,2,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
131,3,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
132,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
132,2,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
132,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
133,1,Hypopituitarism,Anterior pituitary hypofunction,Hypothalamus and pituitary gland disorders,Endo,N
134,1,Incorrect route of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
134,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
134,3,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
135,1,Incorrect route of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
135,2,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
136,1,Injection site discolouration,Injection site reactions,Administration site reactions,Genrl,N
136,2,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
136,3,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
136,4,Injection site vesicles,Injection site reactions,Administration site reactions,Genrl,N
136,5,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
137,1,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
138,1,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
139,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
139,2,Injection site warmth,Injection site reactions,Administration site reactions,Genrl,N
140,1,Blood alkaline phosphatase increased,Tissue enzyme analyses NEC,Enzyme investigations NEC,Inv,N
141,1,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
141,2,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
141,3,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
142,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
142,2,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
142,3,Liquid product physical issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
142,4,Product preparation issue,Product preparation errors and issues,Medication errors and other product use errors and issues,Inj&P,N
143,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
144,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
145,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
146,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
147,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
148,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
148,2,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
148,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
148,4,Feeling hot,Feelings and sensations NEC,General system disorders NEC,Genrl,N
148,5,Hot flush,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
148,6,Nipple pain,Breast signs and symptoms,Breast disorders,Repro,N
148,7,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
148,8,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
